Header Logo

Connection

Paul Thompson to Cell Line, Tumor

This is a "connection" page, showing publications Paul Thompson has written about Cell Line, Tumor.
Connection Strength

0.638
  1. Lewallen DM, Steckler CJ, Knuckley B, Chalmers MJ, Thompson PR. Probing adenylation: using a fluorescently labelled ATP probe to directly label and immunoprecipitate VopS substrates. Mol Biosyst. 2012 Jun; 8(6):1701-6.
    View in: PubMed
    Score: 0.070
  2. Causey CP, Jones JE, Slack JL, Kamei D, Jones LE, Subramanian V, Knuckley B, Ebrahimi P, Chumanevich AA, Luo Y, Hashimoto H, Sato M, Hofseth LJ, Thompson PR. The development of N-a-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-a-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors. J Med Chem. 2011 Oct 13; 54(19):6919-35.
    View in: PubMed
    Score: 0.068
  3. Obianyo O, Causey CP, Jones JE, Thompson PR. Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol. 2011 Oct 21; 6(10):1127-35.
    View in: PubMed
    Score: 0.067
  4. Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, Brown SJ, Rosen H, Cravatt BF, Thompson PR. A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb). 2010 Oct 14; 46(38):7175-7.
    View in: PubMed
    Score: 0.063
  5. Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci. 2011 Feb; 68(4):709-20.
    View in: PubMed
    Score: 0.063
  6. Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 Oct; 12(39):e01014.
    View in: PubMed
    Score: 0.044
  7. Mishra AK, Ye T, Banday S, Thakare RP, Su CT, Pham NNH, Ali A, Kulshreshtha A, Chowdhury SR, Simone TM, Hu K, Zhu LJ, Eisenhaber B, Deibler SK, Simin K, Thompson PR, Kelliher MA, Eisenhaber F, Malonia SK, Green MR. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell Rep. 2024 04 23; 43(4):114041.
    View in: PubMed
    Score: 0.040
  8. Uysal-Onganer P, MacLatchy A, Mahmoud R, Kraev I, Thompson PR, Inal JM, Lange S. Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines. Int J Mol Sci. 2020 Feb 22; 21(4).
    View in: PubMed
    Score: 0.030
  9. Qin H, Liu X, Li F, Miao L, Li T, Xu B, An X, Muth A, Thompson PR, Coonrod SA, Zhang X. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett. 2017 11 28; 409:30-41.
    View in: PubMed
    Score: 0.026
  10. Horibata S, Rogers KE, Sadegh D, Anguish LJ, McElwee JL, Shah P, Thompson PR, Coonrod SA. Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration. BMC Cancer. 2017 05 26; 17(1):378.
    View in: PubMed
    Score: 0.025
  11. Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA. Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells. J Vis Exp. 2015 May 20; (99):e52727.
    View in: PubMed
    Score: 0.022
  12. Witalison EE, Cui X, Hofseth AB, Subramanian V, Causey CP, Thompson PR, Hofseth LJ. Inhibiting protein arginine deiminases has antioxidant consequences. J Pharmacol Exp Ther. 2015 Apr; 353(1):64-70.
    View in: PubMed
    Score: 0.021
  13. Cui X, Witalison EE, Chumanevich AP, Chumanevich AA, Poudyal D, Subramanian V, Schetter AJ, Harris CC, Thompson PR, Hofseth LJ. The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One. 2013; 8(1):e53791.
    View in: PubMed
    Score: 0.019
  14. McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW, Coonrod SA. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer. 2012 Oct 30; 12:500.
    View in: PubMed
    Score: 0.018
  15. Zhang X, Bolt M, Guertin MJ, Chen W, Zhang S, Cherrington BD, Slade DJ, Dreyton CJ, Subramanian V, Bicker KL, Thompson PR, Mancini MA, Lis JT, Coonrod SA. Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor a target gene activation. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13331-6.
    View in: PubMed
    Score: 0.018
  16. Zhang X, Gamble MJ, Stadler S, Cherrington BD, Causey CP, Thompson PR, Roberson MS, Kraus WL, Coonrod SA. Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet. 2011 Jun; 7(6):e1002112.
    View in: PubMed
    Score: 0.017
  17. Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y. Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol. 2008 Aug; 28(15):4745-58.
    View in: PubMed
    Score: 0.013
  18. Yao H, Li P, Venters BJ, Zheng S, Thompson PR, Pugh BF, Wang Y. Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem. 2008 Jul 18; 283(29):20060-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.